545 related articles for article (PubMed ID: 27768700)
1. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
[TBL] [Abstract][Full Text] [Related]
2. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process.
Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Campbell EG
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):694-701. PubMed ID: 28370652
[TBL] [Abstract][Full Text] [Related]
3. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
[TBL] [Abstract][Full Text] [Related]
4. Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey.
Kesselheim AS; Gagne JJ; Franklin JM; Eddings W; Fulchino LA; Avorn J; Campbell EG
J Gen Intern Med; 2016 Jun; 31(6):609-14. PubMed ID: 26883524
[TBL] [Abstract][Full Text] [Related]
5. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
[TBL] [Abstract][Full Text] [Related]
6. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.
Euen BJ; Fadda HM
Res Social Adm Pharm; 2019 Jan; 15(1):77-83. PubMed ID: 29567088
[TBL] [Abstract][Full Text] [Related]
7. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
8. Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.
Kesselheim AS; Gagne JJ
Drug Saf; 2015 Oct; 38(10):849-53. PubMed ID: 26105011
[TBL] [Abstract][Full Text] [Related]
9. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
Kefalas CH; Ciociola AA
Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
[No Abstract] [Full Text] [Related]
10. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
[TBL] [Abstract][Full Text] [Related]
11. FDA's proposed rules on patent listing requirements for new drug and 30-month stays on ANDA approval (proposed Oct. 24, 2002).
Hui YF
Ann Health Law; 2003; 12(2):325-40, table of contents. PubMed ID: 12856462
[TBL] [Abstract][Full Text] [Related]
12. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
13. FDA's Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles.
Chazin H; Woo J; Han J; Grosser S; Luan J
Ther Innov Regul Sci; 2020 Jul; 54(4):758-763. PubMed ID: 32557293
[TBL] [Abstract][Full Text] [Related]
14. FDA notifications. FDA's tentative approval for generic Tenofovir.
AIDS Alert; 2008 Jan; 23(1):11-2. PubMed ID: 18572475
[No Abstract] [Full Text] [Related]
15. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
Choi SH; Lionberger RA
AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
[TBL] [Abstract][Full Text] [Related]
16. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
17. Physicians' Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Health Aff (Millwood); 2024 Jan; 43(1):27-35. PubMed ID: 38190596
[TBL] [Abstract][Full Text] [Related]
18. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
Liu Q; Davit BM; Cherstniakova SA; Dandamudi S; Walters JF; Lee CH; Raines KW; Ren K; Williamson LN; Conner DP
AAPS J; 2012 Mar; 14(1):19-22. PubMed ID: 22130775
[TBL] [Abstract][Full Text] [Related]
19. Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.
Seoane-Vazquez E; Rodriguez-Monguio R; Hansen R
Clin Drug Investig; 2016 Apr; 36(4):281-92. PubMed ID: 26818406
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
